Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Kwee Yong; William Wilson; Ruth M de Tute; Marquita Camilleri; Karthik Ramasamy; Matthew Streetly; Jonathan Sive; Ceri A Bygrave; Reuben Benjamin; Michael Chapman; Selina J Chavda; Elizabeth H Phillips; Maria del Mar Cuadrado; Gavin Pang; Richard Jenner; Tushhar Dadaga; Sumaiya Kamora; James Cavenagh; Laura Clifton-Hadley; Roger G Owen; Rakesh Popat

doi:10.1016/s2352-3026(22)00350-7

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Kwee Yong, William Wilson, Ruth M de Tute, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Jonathan Sive, Ceri A Bygrave, Reuben Benjamin, Michael Chapman, Selina J Chavda, Elizabeth H Phillips, Maria del Mar Cuadrado, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James Cavenagh, Laura Clifton-Hadley, Roger G OwenRakesh Popat

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	The Lancet Haematology
DOIs	https://doi.org/10.1016/s2352-3026(22)00350-7
Publication status	Published - Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s2352-3026(22)00350-7

Cite this

Yong, K., Wilson, W., de Tute, R. M., Camilleri, M., Ramasamy, K., Streetly, M., Sive, J., Bygrave, C. A., Benjamin, R., Chapman, M., Chavda, S. J., Phillips, E. H., Cuadrado, M. D. M., Pang, G., Jenner, R., Dadaga, T., Kamora, S., Cavenagh, J., Clifton-Hadley, L., ... Popat, R. (2023). Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(22)00350-7

Yong, Kwee ; Wilson, William ; de Tute, Ruth M et al. / Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. In: The Lancet Haematology. 2023.

@article{a78eef294f5048cbbe596a98e70b92ca,

title = "Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial",

author = "Kwee Yong and William Wilson and \{de Tute\}, \{Ruth M\} and Marquita Camilleri and Karthik Ramasamy and Matthew Streetly and Jonathan Sive and Bygrave, \{Ceri A\} and Reuben Benjamin and Michael Chapman and Chavda, \{Selina J\} and Phillips, \{Elizabeth H\} and Cuadrado, \{Maria del Mar\} and Gavin Pang and Richard Jenner and Tushhar Dadaga and Sumaiya Kamora and James Cavenagh and Laura Clifton-Hadley and Owen, \{Roger G\} and Rakesh Popat",

year = "2023",

month = feb,

doi = "10.1016/s2352-3026(22)00350-7",

language = "English",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "The Lancet",

}

Yong, K, Wilson, W, de Tute, RM, Camilleri, M, Ramasamy, K, Streetly, M, Sive, J, Bygrave, CA, Benjamin, R, Chapman, M, Chavda, SJ, Phillips, EH, Cuadrado, MDM, Pang, G, Jenner, R, Dadaga, T, Kamora, S, Cavenagh, J, Clifton-Hadley, L, Owen, RG & Popat, R 2023, 'Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial', The Lancet Haematology. https://doi.org/10.1016/s2352-3026(22)00350-7

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. / Yong, Kwee; Wilson, William; de Tute, Ruth M et al.
In: The Lancet Haematology, 02.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

AU - Yong, Kwee

AU - Wilson, William

AU - de Tute, Ruth M

AU - Camilleri, Marquita

AU - Ramasamy, Karthik

AU - Streetly, Matthew

AU - Sive, Jonathan

AU - Bygrave, Ceri A

AU - Benjamin, Reuben

AU - Chapman, Michael

AU - Chavda, Selina J

AU - Phillips, Elizabeth H

AU - Cuadrado, Maria del Mar

AU - Pang, Gavin

AU - Jenner, Richard

AU - Dadaga, Tushhar

AU - Kamora, Sumaiya

AU - Cavenagh, James

AU - Clifton-Hadley, Laura

AU - Owen, Roger G

AU - Popat, Rakesh

PY - 2023/2

Y1 - 2023/2

UR - http://dx.doi.org/10.1016/s2352-3026(22)00350-7

U2 - 10.1016/s2352-3026(22)00350-7

DO - 10.1016/s2352-3026(22)00350-7

M3 - Article

SN - 2352-3026

JO - The Lancet Haematology

JF - The Lancet Haematology

ER -

Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. The Lancet Haematology. 2023 Feb. doi: 10.1016/s2352-3026(22)00350-7

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

UN SDGs

Access to Document

Other files and links

Cite this